IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
• Year: 2008
De cem ber : Takeda be gan con struct ing new re search fa cil i ties in Ja pan, ex pected to com plete be fore the
end of fis cal 2010 (end ing March 2011). This will serve as the cen tre of Takeda’s global re search net work
con sol i dat ing the drug dis cov ery ca pa bil i ties cur rently lo cated in the cities of Osaka and Tsukuba.
Sep tem ber: Takeda Pharmaceuticals Asia Pri vate Lim ited (TPAsia), Takeda’s wholly owned sub sid iary in
Sin ga pore es tab lished and over sees ac tiv i ties in five Asian coun tries (Tai wan Thai land, In do ne sia, China
and the Phil ip pines). At the same time Takeda es tab lished Takeda Clin i cal Re search Sin ga pore Pri vate
Lim ited (TCRS) to serve as its cen ter of clin i cal de vel op ment in the Asia-Oceania region.
Erich Brunn ap pointed new CEO of Takeda Pharmaceuticals Eu rope (TPEU), over see ing ac tiv i ties in six
mar ket ing sub sid iar ies in Eu rope (Ger many, France, the UK, It aly, Aus tria, and Swit zer land) fol low ing
post as pres i dent of GmbH over last six years.
Takeda along with 12 other phar ma ceu ti cal com pa nies has been sued by the At tor ney Gen eral of Kan sas
for al leg edly over charg ing the state’s Medicaid pro gram for drugs pro vided to patients.
July: Takeda is pur su ing a new mu tual agree ment pro ce dure un der US/Ja pan tax agree ments in the hope
of set tling a pay ment of Yen57.1 bil lion which it was or dered to make by Jap a nese tax au thor i ties in June
2006. This fol lowed an of fi cial as sess ment of prof its earned in the US over six years un der agree ments
with the now dis solved jv with Abbott (TAP0 for Prevacid (lansoprazole).
April: Takeda joins HRP ini tia tive to dis cover biomarkers of high risk atherosclerotic plaque, join ing Merck
& Co and AstraZeneca.
Takeda an nounced the in au gu ra tion of its wholly-owned sub sid iary Takeda Bio De vel op ment Cen ter Lim -
ited (Takeda Bio), formed Amgen K.K. which be came a wholly-owned sub sid iary of Takeda in ac cor dance
with a share trans fer agree ment be tween Takeda and Amgen in Feb ru ary 2008. Masaomi Miyamoto will
chair the board of Takeda Bio and Hiroyasu Hakamura will be pres i dent. The com pany has about 140 em -
ploy ees with un dis closed cap i tal. The Amgen Ja pan ac qui si tion re flects Takeda’s plans to re in force its
pipe line while Amgen can ac cel er ate the de vel op ment of its prod ucts in Ja pan and the de ci sion to li cense
its sub sid iary to Takeda came about be cause Takeda showed in ter est in a wide range of prod ucts. Al -
though the cost of the ac qui si tion has not been dis closed, as part of the li cense agree ment in Feb ru ary,
Takeda has ac quired rights to de velop and mar ket al most all of Amgen’s pipe line (13 prod ucts), ex clud ing
Amgen’s main prod ucts which have al ready been li censed to Kirin and Daiichi Sankyo, in ad di tion to
Amgen’s hu man re sources spe cial iz ing in the de vel op ment of biopharmaceuticals. Takeda will pay up to
$837 mil lion in upfront and de vel op ment mile stone pay ments. The most ad vanced prod uct is Vectibix
(panitumumab) for rec tal can cer, for which an NDA is be ing pre pared and as such it is ex pected to con -
trib ute to the achieve ment of Takeda’s mid-term busi ness plan (end ing fis cal 2010). The only other prod -
uct at a late stage of de vel op ment is motesanib (AMG 706) for can cer, and said to be one of the main
driv ers of the deal for Takeda. Other prod ucts li censed in clude a num ber for can cer: AMG 386, AMG 479
and AMG 655; as well as AMG 108 for rheu ma toid ar thri tis and AMG 317 for asthma. The li censed prod -
ucts will strengthen Takeda’s pri or ity fields of can cer and uro log i cal diseases (12 projects underway
including line extensions) as well as CNS and bone joint disease (11 projects underway).
April: Takeda trans ferred all of its shares of Hitachi Inspharma, a jv owned by Hitachi (66%) and Takeda
(34%) to Hitachi as the sched uled two years have passed since the 2006 agree ment.
© 2009 IMS Health In cor po rated or its af fil i ates Page 111